Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Chronic Heart Failure

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 89 articles: HTML format

Single Articles

April 2024
1. SAPP JL, Sivakumaran S, Tang ASL
   Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure. Reply.
   N Engl J Med. 2024;390:1343-1345.
   PubMed    
   
   
   
2. PINTEA BENTEA G, Castro Rodriguez J
   Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.
   N Engl J Med. 2024;390:1344.
   PubMed    
   
   
   
3. BYUN JH, Nguyen S
   Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.
   N Engl J Med. 2024;390:1343-1344.
   PubMed    
   
   
   
4. ROULEAU J
   Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
   N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
   PubMed    
   
   
   
5. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
   Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
   N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
   PubMed     Abstract available
   
   
   January 2024
6. SAPP JL, Sivakumaran S, Redpath CJ, Khan H, et al
   Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.
   N Engl J Med. 2024;390:212-220.
   PubMed     Abstract available
   
   
   December 2023
7. SOHNS C, Tijssen JGP, Sommer P
   Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. Reply.
   N Engl J Med. 2023;389:2496-2497.
   PubMed    
   
   
   
8. KERLEY RN, Joyce E
   Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.
   N Engl J Med. 2023;389:2495-2496.
   PubMed    
   
   
   
9. BLACKWELL JN, Olshansky B, Estes NAM 3rd
   Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.
   N Engl J Med. 2023;389:2495.
   PubMed    
   
   
   
10. KOSIBOROD MN, Borlaug BA, Petrie MC
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
    N Engl J Med. 2023;389:2398-2399.
    PubMed    
    
    
    
11. O'DOWLING R
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
12. WAGNER J
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
13. GAO Y, Gao Y, Qiu H
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2397-2398.
    PubMed    
    
    
    November 2023
14. MENTZ RJ, Hernandez AF
    Ferric Carboxymaltose in Heart Failure with Iron Deficiency. Reply.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    
15. ANKER SD, Filippatos G, Anker MS
    Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    
16. EISENGA MF
    Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    
17. PAYAN-PERNIA S, Perez-Simon JA, Garcia-Erce JA
    Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    October 2023
18. MACK MJ, Leon MB, Thourani VH, Pibarot P, et al
    Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.
    N Engl J Med. 2023 Oct 24. doi: 10.1056/NEJMoa2307447.
    PubMed     Abstract available
    
    
    
19. LEWIS EF
    Catheter Ablation for Atrial Fibrillation in Heart Failure - An Option to Defer Transplantation?
    N Engl J Med. 2023;389:1429-1430.
    PubMed    
    
    
    August 2023
20. 
    Obesity and Heart Failure.
    N Engl J Med. 2023;389:e15.
    PubMed    
    
    
    
21. SOHNS C, Fox H, Marrouche NF, Crijns HJGM, et al
    Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2306037.
    PubMed     Abstract available
    
    
    
22. STAHLI BE, Varbella F, Linke A, Schwarz B, et al
    Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2307823.
    PubMed     Abstract available
    
    
    
23. MARTENS P, Mullens W
    Treating Iron Deficiency in Heart Failure.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMe2308305.
    PubMed    
    
    
    
24. MENTZ RJ, Garg J, Rockhold FW, Butler J, et al
    Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2304968.
    PubMed     Abstract available
    
    
    
25. KOSIBOROD MN, Abildstrom SZ, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963.
    PubMed     Abstract available
    
    
    
26. PINTO YM
    Heart Failure with Preserved Ejection Fraction - A Metabolic Disease?
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMe2309294.
    PubMed    
    
    
    July 2023
27. GARCIA-PAVIA P, Aus dem Siepen F, Donal E, Lairez O, et al
    Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.
    N Engl J Med. 2023;389:239-250.
    PubMed     Abstract available
    
    
    April 2023
28. CHANG LL, DesJardin JT, Albert MA, Ezekowitz J, et al
    Dietary Sodium Restriction in Patients with Heart Failure.
    N Engl J Med. 2023;388:1621-1623.
    PubMed    
    
    
    March 2023
29. LEE DS, Ross HJ
    Trial of an Intervention to Improve Acute Heart Failure Outcomes. Reply.
    N Engl J Med. 2023;388:e46.
    PubMed    
    
    
    
30. PELED H, Dau NQ
    Trial of an Intervention to Improve Acute Heart Failure Outcomes.
    N Engl J Med. 2023;388:e46.
    PubMed    
    
    
    
31. FAN SC, Hsu NC
    Trial of an Intervention to Improve Acute Heart Failure Outcomes.
    N Engl J Med. 2023;388:e46.
    PubMed    
    
    
    
32. HOUSTON BA, Brittain EL, Tedford RJ
    Right Ventricular Failure.
    N Engl J Med. 2023;388:1111-1125.
    PubMed    
    
    
    
33. STONE GW, Abraham WT, Lindenfeld J, Kar S, et al
    Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation.
    N Engl J Med. 2023 Mar 5. doi: 10.1056/NEJMoa2300213.
    PubMed     Abstract available
    
    
    
34. SORAJJA P, Whisenant B, Hamid N, Naik H, et al
    Transcatheter Repair for Patients with Tricuspid Regurgitation.
    N Engl J Med. 2023 Mar 4. doi: 10.1056/NEJMoa2300525.
    PubMed     Abstract available
    
    
    January 2023
35. SOLOMON SD, Vaduganathan M, McMurray JJV
    Dapagliflozin in Heart Failure with Preserved Ejection Fraction. Reply.
    N Engl J Med. 2023;388:288.
    PubMed    
    
    
    
36. GABRIELLI D, Oliva F, Zuccala G
    Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
    N Engl J Med. 2023;388:287-288.
    PubMed    
    
    
    
37. WEIR RAP
    Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
    N Engl J Med. 2023;388:287.
    PubMed    
    
    
    
38. REDFORS B, Omerovic E
    Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
    N Engl J Med. 2023;388:286-287.
    PubMed    
    
    
    
39. ZWECK E, Westenfeld R
    Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
    N Engl J Med. 2023;388:286.
    PubMed    
    
    
    
40. GOYAL P, Horn EM
    More COACHing Needed to Optimize Care after Heart Failure Hospitalization.
    N Engl J Med. 2023;388:82-83.
    PubMed    
    
    
    December 2022
41. MULLENS W, Martens P
    Acute Decompensated Heart Failure, Volume, and Acetazolamide. Reply.
    N Engl J Med. 2022;387:2487.
    PubMed    
    
    
    
42. FAUCHIER L, Maisons V, Halimi JM
    Acute Decompensated Heart Failure, Volume, and Acetazolamide.
    N Engl J Med. 2022;387:2486-2487.
    PubMed    
    
    
    
43. KAPELIOS CJ, Drakos SG, Fang JC
    Acute Decompensated Heart Failure, Volume, and Acetazolamide.
    N Engl J Med. 2022;387:2486.
    PubMed    
    
    
    
44. CULIC V
    Acute Decompensated Heart Failure, Volume, and Acetazolamide.
    N Engl J Med. 2022;387:2485-2486.
    PubMed    
    
    
    November 2022
45. LEE DS, Straus SE, Farkouh ME, Austin PC, et al
    Trial of an Intervention to Improve Acute Heart Failure Outcomes.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2211680.
    PubMed     Abstract available
    
    
    October 2022
46. PERERA D, Clayton T, O'Kane PD, Greenwood JP, et al
    Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2022;387:1351-1360.
    PubMed     Abstract available
    
    
    
47. KIRTANE AJ
    REVIVE-ing a Weak Heart - Details Matter.
    N Engl J Med. 2022;387:1426-1427.
    PubMed    
    
    
    September 2022
48. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    PubMed     Abstract available
    
    
    August 2022
49. FELKER GM
    New Decongestion Strategies in an Evolving Heart Failure Landscape.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMe2209997.
    PubMed    
    
    
    
50. SOLOMON SD, McMurray JJV, Claggett B, de Boer RA, et al
    Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2206286.
    PubMed     Abstract available
    
    
    
51. MARGULIES KB
    DELIVERing Progress in Heart Failure with Preserved Ejection Fraction.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMe2210177.
    PubMed    
    
    
    
52. MULLENS W, Dauw J, Martens P, Verbrugge FH, et al
    Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2203094.
    PubMed     Abstract available
    
    
    May 2022
53. ANKER SD, Butler J, Packer M
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
54. HEERSPINK HJL, Inker L, Greene T
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
55. AMATO J JR
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
56. TRIPOSKIADIS FK, Xanthopoulos A, Iliodromitis EK
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
57. BHATTACHARYYA D, Kar A, Dhumale S
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    November 2021
58. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:1845-1855.
    PubMed     Abstract available
    
    
    September 2021
59. KITZMAN DW, Pastva AM, Mentz RJ
    Physical Rehabilitation in Patients with Heart Failure. Reply.
    N Engl J Med. 2021;385:1340-1341.
    PubMed    
    
    
    
60. DUPONT J, Koppo K, Gielen E
    Physical Rehabilitation in Patients with Heart Failure.
    N Engl J Med. 2021;385:1340.
    PubMed    
    
    
    
61. SCHUTTLER D, Weckbach LT, Brunner S
    Physical Rehabilitation in Patients with Heart Failure.
    N Engl J Med. 2021;385:1339-1340.
    PubMed    
    
    
    
62. FRUSH BW
    Cool Water.
    N Engl J Med. 2021;385:1254-1255.
    PubMed    
    
    
    August 2021
63. ANKER SD, Butler J, Filippatos G, Ferreira JP, et al
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMoa2107038.
    PubMed     Abstract available
    
    
    
64. DRAZNER MH
    SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction - A Win against a Formidable Foe.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMe2113008.
    PubMed    
    
    
    
65. PACKER M, Butler J, Zannad F, Pocock SJ, et al
    Empagliflozin and Major Renal Outcomes in Heart Failure.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMc2112411.
    PubMed    
    
    
    
66. JOYNT MADDOX KE, Orav EJ, Zheng J, Epstein AM, et al
    Year 1 of the Bundled Payments for Care Improvement-Advanced Model.
    N Engl J Med. 2021;385:618-627.
    PubMed     Abstract available
    
    
    May 2021
67. TEERLINK JR, Felker GM, McMurray JJV
    Omecamtiv Mecarbil in Systolic Heart Failure. Reply.
    N Engl J Med. 2021;384:1967-1968.
    PubMed    
    
    
    
68. BELLUMKONDA L
    Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2021;384:1967.
    PubMed    
    
    
    
69. BONAPACE S, Molon G
    Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2021;384:1967.
    PubMed    
    
    
    
70. KOMAMURA K
    Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2021;384:1966-1967.
    PubMed    
    
    
    
71. YEKU OO, Medford AJ, Fenves AZ, Uljon SN, et al
    Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
    N Engl J Med. 2021;384:1943-1950.
    PubMed    
    
    
    
72. ANKER SD, Coats AJS
    Exercise for Frail, Elderly Patients with Acute Heart Failure - A Strong Step Forward.
    N Engl J Med. 2021 May 16. doi: 10.1056/NEJMe2106140.
    PubMed    
    
    
    
73. KITZMAN DW, Whellan DJ, Duncan P, Pastva AM, et al
    Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.
    N Engl J Med. 2021 May 16. doi: 10.1056/NEJMoa2026141.
    PubMed     Abstract available
    
    
    April 2021
74. LEE TH
    Zoom Family Meeting.
    N Engl J Med. 2021;384:1586-1587.
    PubMed    
    
    
    January 2021
75. PACKER M, Zannad F
    Empagliflozin in Heart Failure. Reply.
    N Engl J Med. 2021;384:387-388.
    PubMed    
    
    
    
76. KUMAR S, Sinha S
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:387.
    PubMed    
    
    
    
77. GERARD AO, Favre G, Esnault VLM
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:386-387.
    PubMed    
    
    
    
78. SHANMUGANATHAN M, Goswami RM
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:386.
    PubMed    
    
    
    
79. BHATTACHARYYA D, Kar A
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:385-386.
    PubMed    
    
    
    
80. FAUCHIER L, Fauchier G, Angoulvant D
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:385.
    PubMed    
    
    
    
81. LIN X, Wang S, Huang J
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:384-385.
    PubMed    
    
    
    
82. SWEDBERG K
    Stimulation of Contractility in Systolic Heart Failure.
    N Engl J Med. 2021;384:178-179.
    PubMed    
    
    
    
83. RUDDER M, Russo M, Ventetuolo CE
    Breathing for Two.
    N Engl J Med. 2021;384:61-68.
    PubMed    
    
    
    November 2020
84. BHATT DL, Szarek M, Steg PG, Cannon CP, et al
    Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2030183.
    PubMed     Abstract available
    
    
    
85. TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
    Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2025797.
    PubMed     Abstract available
    
    
    October 2020
86. ARMSTRONG PW, Anstrom KJ, O'Connor CM
    Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply.
    N Engl J Med. 2020;383:1497-1498.
    PubMed    
    
    
    
87. RYAN JJ, Maron BA
    Vericiguat in Heart Failure with Reduced Ejection Fraction.
    N Engl J Med. 2020;383:1497.
    PubMed    
    
    
    
88. WEARDEN J, Hough A, Kaiser S
    Vericiguat in Heart Failure with Reduced Ejection Fraction.
    N Engl J Med. 2020;383:1496-1497.
    PubMed    
    
    
    August 2020
89. KIRCHHOF P, Camm AJ, Goette A, Brandes A, et al
    Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2019422.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.